Biotech Stock Performance Review -- Celgene, Cempra, Editas Medicine, and Epizyme

NEW YORK, July 31, 2017 /PRNewswire/ --

If you want a Stock Review on CELG, CEMP, EDIT, or EPZM then come over to and sign up for your free customized report today. Zacks recently reported that, with the Biotech sector performing well this year, it looks like it is set for a recovery. New product sales ramp up, R&D success and innovation, strong results, a higher number of FDA approvals, and continued strong performance from legacy products are some of the factors that could contribute to a sustained recovery in the sector. Tax reforms and cash repatriation would support a recovery as well. In today's pre-market research, takes a closer look at the most recent performances of Celgene Corp. (NASDAQ: CELG), Cempra Inc. (NASDAQ: CEMP), Editas Medicine Inc. (NASDAQ: EDIT), and Epizyme Inc. (NASDAQ: EPZM). These free stocks reports are currently available on Simply sign up for your complimentary member access at: Celgene 

Summit, New Jersey headquartered Celgene Corp.'s shares declined 0.04%, finishing last Friday's session at $134.10. A total volume of 3.79 million shares was traded. Over the previous three months and since the start of this year, the stock has advanced 8.10% and 15.85%, respectively. The Company's shares are trading above their 50-day and 200-day moving averages by 6.04% and 12.00%, respectively. Additionally, shares of Celgene, which discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide, have a Relative Strength Index (RSI) of 56.47.

On July 28th, 2017, research firm Stifel initiated a 'Buy' rating on the Company's stock, with a target price of $155 per share.

On July 28th, 2017, Celgene announced that its management will present at the Canaccord Genuity 37th Annual Growth Conference August 09th, 2017, at 3:00 p.m. ET in Boston to provide an overview of the Company. The conference will be webcast live and will be available under the Investor Relations section of the Company's website. Your complete research report on CELG can be retrieved for free at: Cempra 

On Friday, shares in Chapel Hill, North Carolina headquartered Cempra Inc. ended the session 1.22% higher at $4.15. The stock recorded a trading volume of 377,387 shares. The Company's shares have surged 48.21% on an YTD basis. The stock is trading above its 50-day moving average by 0.39%. Moreover, shares of Cempra, which focuses on developing anti-infectives for the acute care and community settings to meet critical medical needs in the treatment of infectious diseases in North America, have an RSI of 46.74.

On July 20th, 2017, Cempra announced that it will report Q2 2017 financial results before US financial markets open on August 09th, 2017. Management will host a webcast and conference call at 8:45 a.m. ET that same day to discuss the financial results and provide a corporate update. A live webcast of the call will be available under the investor relations section of the Company's website. A free report on CEMP is just a click away at: Editas Medicine 

Cambridge, Massachusetts-based Editas Medicine Inc.'s stock surged 7.80%, to close the day at $17.14. A total volume of 1.09 million shares was traded, which was above their three months average volume of 711,570 shares. The Company's shares have advanced 5.61% since the start of this year. The stock is trading 4.34% above its 50-day moving average. Additionally, shares of Editas Medicine, which operates as a genome editing company, have an RSI of 58.21.

On July 14th, 2017, research firm SunTrust initiated a 'Hold' rating on the Company's stock, with a target price of $17 per share. Sign up for your complimentary research report on EDIT at: Epizyme 

Shares in Cambridge, Massachusetts headquartered Epizyme Inc. recorded a trading volume of 341,489 shares. The stock ended at $12.15, down 1.62% from the last trading session. The Company's shares have gained 0.41% on an YTD basis. The stock is trading below its 200-day moving average by 7.67%. Furthermore, shares of Epizyme, which discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the US, have an RSI of 33.49.

On July 24th, 2017, Epizyme announced that the National Cancer Institute (NCI), part of the National Institutes of Health, has initiated its NCI-COG Pediatric MATCH study, which includes a phase-2 evaluation of tazemetostat as one of its treatment arms. This multi-institutional study will evaluate tazemetostat as a monotherapy for pediatric patients with advanced solid tumors - including CNS tumors, non-Hodgkin lymphoma, or histiocytic disorders - that harbor gain of function mutations in EZH2, or loss of function mutations in the SWI/SNF complex subunits SMARCB1 or SMARCA4. Register for free on and download the latest research report on EPZM at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA(R) charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


        For any questions, inquiries, or comments reach out to us directly. If you're a company
         we are covering and wish to no longer feature on our coverage list contact us via
         email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: 
        Phone number: (207)331-3313 
        Office Address: 377 Rivonia Boulevard, Rivonia, South Africa 

  CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA